Meeting
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
Authors
Lin-Quan Tang
Sun Yat-sen University Cancer Center, Guangzhou, China
Lin-Quan Tang , Guo-Dong Jia , xiao-Fei Lv , Siyi Xie , Yu Chen , Ji-Bin Li , Xiao Yun Li , Manyi Zhu , Sai Lan Liu , LiTing Liu , Xue-Song Sun , Shanshan Guo , Dong-Hua Luo , Qiu-Yan Chen , Hai-Qiang Mai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04547088, NCT04548271
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6042)
DOI
10.1200/JCO.2022.40.16_suppl.6042
Abstract #
6042
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
First Author: Hu Liang
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang
Poster
2021 Gastrointestinal Cancers Symposium
Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
First Author: Feng Wang
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
First Author: Dongmei Ji